The drugmaker's full-year results didn't seem to move the needle for investors who are instead focused on future growth prospects and innovation
In this article
Drugmakers Roche
and Sanofi’s
latest earnings were largely as expected, with the companies talking up the potential of experimental medicines ahead of a looming “patent cliff” for Big Pharma.
Both companies’ stocks were down less than 1% on Thursday after reporting earnings before the bell.
The new year is shaping up to be a defining year following a dramatic 2025, and one where the impact from last year's…
Big pharma is grappling with new drug pricing deals and roughly $300 billion in potential lost revenue from patent expirations of…
Investors are scrutinizing the prospects for some drugs in the pipeline following a string of recent rejections from the U.S.…
Biogen could see lower royalties for Ocrevus after its patent expires , but it has developed other medicines that will support…
Eli Lilly, Merck, Gilead, Bristol Myers Squibb and AbbVie, among other pharmaceutical companies, are slated to report…
Currency effects weighed on the Swiss drugmaker's first-quarter earnings
